CUE analyst estimates
Cue Biopharma (CUE) analyst ratings, the average price target and its range, and every firm's latest call.
CUE analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 1, 2026 | B.Riley Financial | B.Riley Reiterates Buy Rating on Cue Biopharma (CUE) | $83.00 |
| Nov 15, 2024 | Jefferies | Cue Biopharma (CUE) PT Lowered to $4 at Jefferies | $4.00 |
| Jul 26, 2024 | JMP Securities | Cue Biopharma price target lowered to $2 from $15 at JMP Securities | $2.00 |
| Mar 13, 2024 | Jefferies | Jefferies Starts Cue Biopharma (CUE) at Buy, 'Following Nature's "Cues" W/ Targeted IL-2 Therapy' | $6.00 |
| Nov 20, 2022 | Piper Sandler | Cue Biopharma initiated with an Overweight at Piper Sandler | $7.00 |
- 0 firms rate CUE: 0 buy, 0 hold, 0 sell.
- The average price target is $83.00 from None analysts, from $83.00 to $83.00.
Updated 2026-11-18 05:48 UTC